Literature DB >> 8789768

Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol.

M J Kemper1, E Harps, H H Hellwege, D E Müller-Wiefel.   

Abstract

UNLABELLED: Hyperkalaemia is a life-threatening emergency and infusion of glucose with insulin has so far been regarded as the standard treatment of choice. Recently the beta-2 stimulatory drug salbutamol has been shown to be an effective agent to treat hyperkalaemia by inducing a shift of potassium into the intracellular compartment. We treated 15 children aged 0.1-14 (mean 5.2) years suffering from acute hyperkalaemia (mean level 6.6 +/- 0.54, range 5.9-7.7 mmol/l) with a single infusion of salbutamol (5 micrograms/kg over 15 min). Serum potassium concentrations decreased significantly within 30 min to levels of 5.74 +/- 0.53 and 4.92 +/- 0.53 mmol/l after 120 min (P < 0.001, respectively). No side-effects occurred other than a light increase in heart rate in 3 patients.
CONCLUSION: A single intravenous infusion of salbutamol at a dose of 5 micrograms/kg is a highly effective treatment for hyperkalaemia with minimal clinical side-effects. The effect lasts for at least 120 min and may reverse hyperkalaemia in some patients without further interventions so that salbutamol seems justified as the first choice treatment for this condition in childhood.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789768     DOI: 10.1007/bf01955188

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients.

Authors:  M Allon; C Copkney
Journal:  Kidney Int       Date:  1990-11       Impact factor: 10.612

2.  Treatment of hyperkalaemia with intravenous salbutamol.

Authors:  I A Murdoch; R Dos Anjos; G B Haycock
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

Review 3.  Regulation of the Na,K-pump in skeletal muscle.

Authors:  T Clausen; M E Everts
Journal:  Kidney Int       Date:  1989-01       Impact factor: 10.612

4.  Intracellular pH and K+ of cardiac and skeletal muscle in acidosis and alkalosis.

Authors:  P A Poole-Wilson; I R Cameron
Journal:  Am J Physiol       Date:  1975-11

5.  Acute increase in plasma osmolality as a cause of hyperkalemia in patients with renal failure.

Authors:  G Conte; A Dal Canton; P Imperatore; L De Nicola; G Gigliotti; N Pisanti; B Memoli; G Fuiano; C Esposito; V E Andreucci
Journal:  Kidney Int       Date:  1990-08       Impact factor: 10.612

6.  Treatment and prevention of hyperkalemia in end-stage renal disease.

Authors:  M Allon
Journal:  Kidney Int       Date:  1993-06       Impact factor: 10.612

7.  Treatment of attacks in hyperkalaemic familial periodic paralysis by inhalation of salbutamol.

Authors:  P Wang; T Clausen
Journal:  Lancet       Date:  1976-01-31       Impact factor: 79.321

8.  Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure.

Authors:  A Blumberg; P Weidmann; S Shaw; M Gnädinger
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

9.  Treatment of hyperkalaemia using intravenous and nebulised salbutamol.

Authors:  R J McClure; V K Prasad; J T Brocklebank
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

10.  Treatment of hyperkalaemia in renal failure: salbutamol v. insulin.

Authors:  X M Lens; J Montoliu; A Cases; J M Campistol; L Revert
Journal:  Nephrol Dial Transplant       Date:  1989       Impact factor: 5.992

View more
  2 in total

Review 1.  Pathogenesis, diagnosis and management of hyperkalemia.

Authors:  Anja Lehnhardt; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

2.  Suppressive effects of procaterol on expression of IP-10/CXCL 10 and RANTES/CCL 5 by bronchial epithelial cells.

Authors:  Ka-Pan Lam; Yu-Te Chu; Chang-Hung Kuo; Wei-Li Wang; Teck-Siang Tok; Yow-Yue Chin; Solomon Chih-Cheng Chen; Chih-Hsing Hung
Journal:  Inflammation       Date:  2011-08       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.